Hotline International – Top Studies 2013/2014 – Session II
Vorsitz: M. Kelm (Düsseldorf), N. Marx (Aachen)
| PATENT and CHEST studies of Riociguat for the treatment of pulmonary arterial hypertension and CTEPH (2 x NEJM 2013) | ||
| 11:30 | (V1211) | Sprecher: |
| A. Ghofrani (Gießen) | ||
| 11:42 | (V1212) | Diskutant: |
| S. Rosenkranz (Köln) | ||
| Panel-Diskussion | ||
Cryptogenic Stroke and underlying Atrial Fibrillation (CRYSTAL AF) (ACC 2014) |
||
| 11:52 | (V571) | Sprecher: |
| J. Brachmann (Coburg) | ||
| 12:04 | (V572) | Diskutant: |
| M. Dichgans (München) | ||
| Panel-Diskussion | ||
| Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial (JAMA 2013) |
||
| 12:14 | (V1215) | Sprecher: |
| B. Pieske (Graz, AT) | ||
| 12:26 | (V1216) | Diskutant: |
| J. Bauersachs (Hannover) | ||
| Panel-Diskussion | ||
| A 52-Week Randomized, Double-blind, Placebo Controlled Study of Evolocumab in Hyperlipidemia: The DESCARTES Study (ACC 2014) | ||
| 12:36 | (V1217) | Speaker: |
| E. A. Stein (Cincinnati, US) | ||
| 12:48 | (V1218) | Diskutant: |
| W. Koenig (Ulm) | ||
| Panel-Diskussion |
| 13:15 - 14:15 | DGK-Mitgliederversammlung Teil 1 in Saal 4 |